Sign in

Subra Sankar

Senior Vice President, Product Development at Nautilus Biotechnology
Executive

About Subra Sankar

Subra Sankar (age 65) is Senior Vice President, Product Development at Nautilus Biotechnology, serving since June 2021; he previously led product development roles at GenapSys and engineering at LumaSense Technologies. He holds a B.Tech. in Aeronautical Engineering (IIT Madras), an M.S. and Ph.D. in Aerospace Engineering (Georgia Tech), and an MBA (UC Berkeley Haas) . Nautilus did not disclose executive-specific TSR or financial performance metrics for Sankar; company-wide 2024 bonus payouts to named executive officers were zero due to not meeting threshold goals under the 2024 Bonus Plan .

Past Roles

OrganizationRoleYearsStrategic Impact
GenapSys Inc.SVP, Product Development2019–2020Led product development at DNA sequencing technology company
GenapSys Inc.VP, Product Development2015–2019Product development leadership
LumaSense Technologies, Inc.VP, Engineering & Development2014–2015Engineering and development leadership in sensing solutions

External Roles

No outside public company directorships or external governance roles disclosed for Sankar in company filings .

Fixed Compensation

  • Not disclosed for Sankar (he is not a named executive officer in 2023–2024–2025 proxies); executive compensation tables cover Sujal Patel, Parag Mallick, and (2024) Anna Mowry / (2025) Kentaro Suzuki .

Performance Compensation

  • Nautilus operates an Executive Incentive Compensation Plan with corporate performance goals; however, 2024 bonuses were not paid to named executive officers due to threshold goals not being met, and Sankar’s specific participation/payouts are not disclosed .

Equity Ownership & Alignment

Reported insider transactions (Form 4):

DateSecurityTransactionSharesPrice ($)Notes
2022-09-26Common StockOpen-market purchase10,0002.025 (weighted avg)Purchases in $2.00–$2.05 range; includes 1,250 ESPP shares in holdings as of June 1, 2022
2022-09-27Common StockOpen-market purchase5,0002.0298 (weighted avg)Purchases in $2.02–$2.04 range
2025-03-03Stock Option (Right to Buy)Option grant160,0001.24 (strike)25% vests on 2026-01-01; remaining vests monthly over 36 months; expires 2035-03-03

Outstanding/granted options and vesting:

Grant/PlanStrike ($)ExpirationAmount (shares)Vesting
2017/2021 Plan aggregate (as of S-8, 2021)VariousVarious725,614192,509 vest on 2022-01-03; 533,105 vest monthly over 36 months thereafter
Option grant 2025-03-031.242035-03-03160,00025% on 2026-01-01; balance monthly over 36 months

Alignment and risk policies:

  • Pledging and hedging of company stock are prohibited for employees and officers (short sales, derivatives, collars, exchange funds, margin accounts) under Nautilus’s insider trading policy .
  • Stock ownership guidelines: compensation committee monitors compliance “with any stock ownership guidelines,” but specific executive guidelines are not disclosed .

Employment Terms

ItemDetail
Role start dateSenior Vice President, Product Development since June 2021
Change-in-control agreementExists (Exhibit 10.18 referenced in filings); specific severance multiples not disclosed for Sankar
Equity acceleration (CIC)100% acceleration of unvested equity if terminated without cause or for good reason during CIC period, per 2021 S-8 footnote
Non-compete / non-solicitNot disclosed in proxies for Sankar
ClawbackCompany-wide Dodd-Frank compliant compensation recovery (effective Oct 2, 2023)
Hedging/pledgingProhibited under insider trading policy

Investment Implications

  • Ownership alignment appears positive: insider open-market share purchases in 2022 and new option grant in 2025 support continued alignment and retention via multi-year vesting; hedging/pledging bans reduce misalignment risk .
  • Equity acceleration under CIC protects the executive but can create incremental transaction dilution; severance cash multiples for Sankar are not disclosed, limiting precise modeling of potential change-of-control costs .
  • Pay-for-performance environment: no 2024 bonuses paid to named executive officers under the Incentive Plan due to under-threshold attainment, signaling tighter cash incentive alignment; Sankar’s specific payouts are not disclosed, so trading signals should rely on Form 4 activity and vesting schedules rather than cash bonus outcomes .